Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance
GLP-1RA therapy does not affect tumor growth kinetics in patients with low-risk papillary thyroid carcinoma on AS. Further studies with larger cohorts and extended follow-up are warranted to validate the safety of GLP-1RA use in patients with thyroid carcinomas undergoing active surveillance.
Authors
- Armando Patrizio (ORCID: https://orcid.org/0000-0003-1090-4794)
- Robert Michael Tuttle (ORCID: https://orcid.org/0000-0001-9899-9702)
- Laura Boucai (ORCID: https://orcid.org/0000-0002-8852-1120)
- Samantha Newman (ORCID: https://orcid.org/0000-0003-2404-4318)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1210/jendso/bvaf182
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute